meta
|
evidence
oncology
Living systematic review and meta-analysis
RET gene alteration defined cancer
2
glioblastoma (GB)
1
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab
All patients
PD-L1 < 1%
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Diarrhoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
deaths (OS)
glioblastoma (GB)
glioblastoma (GB)
metastatic glioblastoma (mGB) - 1st line (L1)
metastatic glioblastoma (mGB) - 1st line (L1)
versus bevacizumab
nivolumab alone vs. bevacizumab
1
certainty unassessable
+4%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open